- Telehealth visits
- Insurance plan information
Adam L. Boxer, MD, PhD
Neurology (Behavioral Neurology) • Neurology- Telehealth visits
- Insurance plan information
Adam L. Boxer, MD, PhD
Neurology (Behavioral Neurology) • Neurology- Telehealth visits
- Insurance plan information
On this page
About me
Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical parkinsonism – in particular, corticobasal degeneration and progressive supranuclear palsy.
Boxer obtained his medical and doctoral degrees as part of the Medical Scientist Training Program at New York University School of Medicine, a program funded by the National Institutes of Health. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF.
Boxer directs the clinical neurology research unit for the Sandler Neurosciences Center at Mission Bay, as well as the clinical trials program for Alzheimer's disease and frontotemporal dementia at the Memory and Aging Center.
Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Alzheimer's Foundation Alzheimer's Award and a 2009 Hellman Family Foundation fellowship.
Education & training
Board certification
- Neurology, American Board of Psychiatry/Neurology-Psychiatry
Fellowship
- Neurobehavior, UCSF School of Medicine -GME
Degree
- MD, New York University School of Medicine
Academic title
- Professor-in-Residence
My expertise
Locations
My research
Clinical trials
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)Opens in a new window
Recruiting
Compare rates of change in whole brain and regional volumes between asymptomatic f-FTLD and symptomatic f- and s-FTLD, measured using MRI.Alzheimer's Tau Platform: Master ProtocolOpens in a new window
Recruiting
To determine whether at least one tau therapy, either alone or in combination with donanemab, will produce a greater reduction in brain tau deposition as measu...The Progressive Supranuclear Palsy Clinical Trial PlatformOpens in a new window
Recruiting
Change in disease severity as measured by the 15-item modified Progressive Supranuclear Palsy Rating Scale (mPSPRS-15) in which the minimum score is 0 and the...
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.